Compugen Earnings Call Transcripts
Fiscal Year 2026
-
The company showcased its AI-driven immune-oncology pipeline, highlighting COM701 and rilvegostomig, with major partnerships and robust financials. Key trials target platinum-sensitive ovarian cancer and innovative bispecific antibody strategies, with pivotal data expected from 2027 onward.
-
AstraZeneca's rilvegostomig is being tested in 11 phase III trials, leveraging a bispecific, Fc-reduced format and novel biomarker-driven combinations, with key readouts expected after 2027. COM701 is being evaluated in platinum-sensitive ovarian cancer, and an IL-18BP program with Gilead is advancing in phase I.
-
COM701 is advancing in a randomized trial for platinum-sensitive ovarian cancer, aiming to extend progression-free survival, with interim data expected in Q1 2027. Partnerships with AstraZeneca and Gilead provide financial stability and support a robust early pipeline focused on novel immuno-oncology targets.
Fiscal Year 2025
-
Cash runway extended into 2029 after a $65M AstraZeneca deal, with strong revenue growth and a shift to profitability in 2025. Key clinical programs advanced globally, with major milestones expected in 2026–2027.
-
The company highlighted its AI-driven immuno-oncology pipeline, including COM701 for ovarian cancer and GS-0321 for cytokine modulation, both advancing in clinical trials. Strategic partnerships with AstraZeneca and Gilead provide significant milestone and royalty opportunities, with a cash runway into Q3 2027.
-
Solid cash position supports operations into Q3 2027, with key clinical programs advancing and major catalysts expected in 2026. Revenue declined year-over-year due to milestone timing, while R&D and G&A expenses decreased. Clinical data and partnerships with AstraZeneca and Gilead drive future value.
-
Leadership transition and a focus on AI-driven immuno-oncology mark a new phase, with a robust pipeline, major pharma partnerships, and strong financials supporting growth. Key clinical readouts and milestone opportunities are expected in the next few years.
-
The company leverages its Unigen™ AI platform to discover novel immuno-oncology targets, advancing assets like COM701 and COM902 through strategic partnerships with AstraZeneca and Gilead. The MAIA ovarian cancer study is a key focus, with interim results expected in 2026. Financially, a $94M cash position supports operations into 2027.
-
Leadership transition and strong cash position support ongoing clinical progress in immuno-oncology, with key trials advancing and major partnerships offering significant milestone potential. Revenue declined year-over-year due to milestone timing, but cash runway extends into 2027.
-
Leadership transitions and a strong cash position support ongoing clinical and early-stage immuno-oncology programs. Q1 2025 saw stable net loss and lower R&D expenses, with key trials advancing and significant partnership milestones possible from AstraZeneca and Gilead.
-
The company is advancing its AI-driven immunotherapy pipeline, with COM701 in a pivotal adaptive trial for platinum-sensitive ovarian cancer. Strategic partnerships, notably with AstraZeneca, and a strong IP position support growth, while ongoing platform innovation aims to expand the pipeline.
-
The company presented its immuno-oncology pipeline, highlighting COM701’s move into platinum-sensitive ovarian cancer and the differentiated profile of its TIGIT antibody. Strategic collaborations with AstraZeneca and Gilead offer significant milestone and royalty potential, while adaptive trial designs and AI-driven discovery underpin future growth.
-
The company leverages AI-driven discovery to advance first-in-class immuno-oncology assets, with major partnerships and clinical programs underway. Key deals with AstraZeneca and Gilead provide significant milestone and royalty potential, and a strong cash position supports operations into 2027.
-
The discussion highlighted progress in immuno-oncology assets, including phase 3 trials for a TIGIT/PD-1 bispecific, promising data for a PVRIG antibody in ovarian cancer, and a novel IL-18BP program. The company’s validated AI platform continues to drive new target discovery.
-
Recent data show durable responses for triplet therapy in platinum-resistant ovarian cancer, supporting the move to a COM701 monotherapy trial in platinum-sensitive patients with a targeted 50% PFS improvement. Strategic partnerships with AstraZeneca and Gilead advance pipeline assets, with significant milestone and royalty potential.
Fiscal Year 2024
-
Key 2024 milestones included advancing COM701 and GS0321, with strong cash reserves of $103.3M and a runway into 2027. Revenue declined year-over-year, but milestone payments from Gilead and AstraZeneca supported operations. Interim data for COM701 is expected in 2026.
-
Recent data show durable responses and good safety for triplet therapy in platinum-resistant ovarian cancer, with a new trial of COM701 monotherapy in platinum-sensitive patients set to begin soon. Pipeline progress includes a phase 1 start for COM503 and ongoing partnerships with Gilead and AstraZeneca.
-
Q3 2024 saw strong financial performance with $17.1M in revenue and a $1.3M net profit, driven by milestone payments and reduced R&D expenses. Clinical data confirmed durable, well-tolerated responses for COM701 combinations in ovarian cancer, supporting a new maintenance therapy trial in 2025.
-
The session highlighted a robust immunotherapy pipeline, strategic partnerships, and promising clinical data in hard-to-treat cancers. Key milestones include a strong cash position, upcoming trial results, and major data presentations by partners in Q4 and September.
-
Q2 2024 saw FDA IND clearance for COM503, a $30M milestone, and strong cash position. Revenue rose to $6.7M, net loss narrowed, and key clinical data in ovarian cancer is expected in Q4. Partnerships and pipeline advances support a positive outlook.